In-Depth Research On:
Eli Lilly & Co (LLY)

Sign Up Now to Download a Free Research Report on LLY

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts

Select your areas of interest / would you like to receive the newsletter?




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Eli Lilly & Co

Eli Lilly and Co. shares increased 0.03 percent to close at $58.90 a share Friday. The stock traded between $58.83 and $59.95 on volume 2.88 million shares traded. The company recently announced that its treatment for liver cancer, CYRAMZA™ (ramucirumab), failed to meet its primary endpoint in a recent Phase III trial. Shares of Eli Lilly have gained approximately 15.0 percent year-to-date.

Going forward ... (see research report)


RESEARCH REPORT ON LLY
Download Free Report Now


Preview Pages of Actual Research Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on